Vertaling van "million minus " (Nederlands → Frans) :

TERMINOLOGIE

labium minus
Petite lèvre

labium (majus)(minus) | penis | perineum | scrotum | testis | vagina | vulva
Lèvres (grandes) (petites) Pénis Périnée Scrotum Testicule Vagin Vulve

labium (majus)(minus) | penis | scrotum | testis | vulva
Lèvres (grandes) (petites) Pénis Scrotum Testicule Vulve

os capitatum [os magnum] | os hamatum [os unciforme] | os lunatum [os semilunare] | os pisiforme | os trapezium [os multangulum majus] | os trapezoideum [os multangulum minus] | os triquetrum [os cuneiforme van pols]
Grand os Os crochu Pisiforme Pyramidal Semi-lunaire Trapèze Trapézoïde

anus | billen | buikwand | flank | labium (majus)(minus) | lies | mamma | penis | perineum | regio interscapularis | rug [elk deel] | scrotum | testis | thoraxwand | vulva
aine anus dos [toute partie] flanc lèvre de la vulve (grande) (petite) paroi abdominale paroi thoracique pénis périnée région fessière région interscapulaire scrotum sein testicule vulve

IN-CONTEXT TRANSLATIONS

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus